EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, placebo-controlled, double-blind trial of interferon alpha-2b plus ribavirin vs interferon alone for retreatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon A 48 week review



Multicenter, placebo-controlled, double-blind trial of interferon alpha-2b plus ribavirin vs interferon alone for retreatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon A 48 week review



Hepatology 30(4 PART 2): 201A




(PDF 0-2 workdays service: $29.90)

Accession: 035349980

Download citation: RISBibTeXText



Related references

Double-blind, multicenter, placebo-controlled trial of interferon alpha-2B plus ribavirin versus interferon alpha-2B for retreatment of relapsers and non-responders with chronic hepatitis C who failed previous treatment with interferon. Gastroenterology 116(4 PART 2): A1202, April, 1999

Double-blind, placebo-controlled trial of interferon alpha-2b plus ribavirin versus interferon alpha-2b for retreatment of patients with chronic hepatitis C who failed previous treatment with interferon alpha. Hepatology 28(4 PART 2): 703A, 1998

Multicenter, randomized, double-blind, placebo-controlled trial of interferon-alpha with and without amantadine as treatment for IFN-alpha non-responders with chronic hepatitis C. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A149, April, 2000

Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: a clinical trial of interferon relapsers and non-responders. Journal of the Formosan Medical Association 100(10): 662-667, 2002

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. Journal of Hepatology 34(1): 128-133, January, 2001

Treatment of chronic hepatitis C with interferon alpha 2b plus for 24 weeks or 48 weeks in non-responders and relapsers to a previous course of interferon alone Preliminary results of a randomised controlled trial. Journal of Hepatology 30(SUPPL 1): 126, 1999

Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut 53(1): 130-135, January, 2004

Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. Gut 53(1): 130-135, 2003

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. Journal of Hepatology 31(1): 1-7, 1999

Therapeutic efficacy of interferon+ribavirin , 6 vs 12 months, in chronic hepatitis C patients who were non-responders or relapsers to a previous treatment with interferon. Journal of Hepatology 30(SUPPL 1): 136, 1999

Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatology Research 28(3): 125-136, 2004

Retreatment for chronic Hepatitis C of interferon non-responder patients Preliminary results of a multicenter randomized controlled trial of interferon plus ribavirin versus interferon alone. Hepatology 28(4 PART 2): 374A, 1998

A systematic review on interferon-alpha with or without ribavirin for interferon naive, non-responders, and relapsers with chronic hepatitis C. Journal of Hepatology 34(Supplement 1): 180, April, 2001

Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers. Jpma. Journal of the Pakistan Medical Association 62(4): 338-343, 2012

A phase II randomized, double-blind, placebo-controlled, multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin. Hepatology 34(4 Pt 2): 350A, October, 2001